|
Therapeutic oligonucleotides are being developed for cancer, viral, autoimmune and neurodegenerative diseases. New delivery platforms such as mRNA, circular RNA and RNA micelles introduce complex analytical challenges.
As these therapies advance, bioanalytical methods must evolve to meet regulatory demands. QPS is a full service CRO that provides a full range of bioanalytical services to support all oligonucleotide development.
Explore the QPS white paper showcasing cutting-edge methods for metabolite identification, profiling, and quantitation in therapeutic oligonucleotides.
|